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Biobanks are increasingly being established to act as mediators between patient-
donors and researchers. In practice, some of these will close. This paper details
the experiences of one such bank. We report interviews with the bank’s staff and
oversight group during the period when the bank ceased biobanking activity,
reconﬁgured as a disseminator of best practice, before then closing altogether.
The paper makes three distinct contributions: (i) to provide a detailed account
of the establishment, operational challenges, and eventual closure of the
bank, which makes clear the rapid turnover in a cycle of promise and
disappointment; (ii) to explore this in terms of a novel analytical focus upon
ﬁeld, institutional, and individual expectations; and (iii) to use this typology
to demonstrate how, even after the bank’s closure, aspects of its work were
reconﬁgured and reused in new contexts. This provides a unique empirical
analysis of the under-reported issue of biobank closure.
Keywords: biobanks; promise; expectations; closure; ﬁeld; institution;
individual
The last two decades have seen an increase in the formalization of tissue collections
into tissue banks: centralized holdings of human tissue for research or clinical pur-
poses. These activities form part of a constellation of promises about maximizing
the socio-technical beneﬁt of storing and distributing human biological material.
Almost all biobanks identify facilitating patient care as their long-term goal,
being mediators between patient-donors, clinicians, and researchers. To some,
this movement is a biobanking revolution, due to its scale, swiftness, and boldness
of vision; to others, talk of a revolution is to exaggerate the promise and downplay
the challenges facing the ﬁeld (Tutton 2007). Regardless of the success of any
broader revolution, some individual biobanks will fail to deliver upon their
initial promise. Some will underperform, some will be merged with other biobanks,
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and some will ultimately close. Detailing this issue, Cadigan et al. (2013) discuss
the unexpected ethical dilemmas faced by biobank managers on the discrepancy
between the hope that their bank will exist permanently and the knowledge that
their funding is limited. In a related study, Cadigan et al. (2014) report the issue
of biobank specimen underutilization, and the concerns of some biobank managers
that fewer people approach them to access tissue than had been anticipated.
Cadigan et al. (2014) highlight parallel issues with biobank mergers. These impor-
tant works, and our own (cf. Tupasela and Stephens 2013), support Zawati, Borry,
and Howard (2011) and call for social scientists and biobanking professionals to
take seriously the practical and ethical issues inherent in the under-considered
issue of biobank closure.
Consideration of these issues is timely as the number of disbanded biobanks
increases. In late 2009 the UK Human Tissue Bank closed (Coleman 2010), the
US Armed Forces Institute of Pathology and the Singapore Biobank closed in
2011 (Chang 2011; McCook 2011), and the Massachusetts Stem Cell Bank
closed in 2012 (Johnson 2013). Private sector closures and reconﬁgurations
include the collapse of Ardais in 2005 that led to the selling of its biosamples to
Cytomyx Holdings and its bespoke software to Gulfstream (BioIform 2006), and
SeraCare Life Sciences that in 2013 sold its biobank to refocus on producing in
vitro diagnostic products (Vaught et al. 2011; Seiffert 2013).
In this paper we report the practical experience of an additional biobank – an
anonymous disease-speciﬁc biomedical research tissue bank here referred to with
the pseudonym “Xbank” – that scaled back its activities and then, two years
later, closed. In doing so, we provide the ﬁrst analysis of biobank closure with
data collected inside the organization as closure occurred. We embed our
account within the sociology of expectations literature (Brown and Michael
2003; Hedgecoe and Martin 2003) to further theorize Cadigan et al.’s (2013)
observed discrepancy between aspiration and deliverability in biobanking. Our
paper makes three distinct contributions: (i) to provide a detailed account of the
establishment, operational challenges, and eventual closure of Xbank – as recog-
nized by the individuals involved – in a form that makes clear the rapid turnover in
a cycle of promise and disappointment at the bank, (ii) to explore this in terms of
our novel focus upon ﬁeld, institutional, and individual expectations, and (iii) to use
this typology to demonstrate how, even after Xbank’s closure, aspects of its promis-
sory narrative, material holdings, ethical labor, and infrastructural capital were
reconﬁgured and reused in new and different contexts. By focusing upon the
under-reported issue of tissue bank closure we make a contribution to the
broader “sociology of biobanking” (Lipworth, Forsyth, and Kerridge 2011).
The sociology of expectations: ﬁeld, institutional, and individual
The sociology of expectations is a core strand in the social analysis of biomedicine
(Hedgecoe 2004; Kitzinger and Williams 2005; Pickersgill 2011) and biobanking
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(Tutton 2007; Stephens, Atkinson, and Glasner 2008a; Murtagh et al. 2011), and
has growing inﬂuence in other areas as diverse as IT procurement (Pollock andWil-
liams 2010), car fuels (Bakker 2010), and laboratory-grown meat (Chiles 2013).
Perhaps most cleanly articulated by Brown and Michael’s (2003) twin notions of
retrospecting prospects and prospecting retrospects – documenting the recollection
of past futures and observing how prospects are deployed in the moment to con-
struct futures – a key component has remained a focus of the performativity of
future-orientated narratives (Van Lente 1993; Brown, Rappert, and Webster
2000). This literature shows how expectations become “managed” by professionals
(Koay and Sharp 2014), and can be embedded within organizations (Pollock and
Williams 2010), “communities of promise” (Brown and Kraft 2006), or material
phenomena like images (Lo¨scha 2006) and buildings (Thrift 2006; Stephens,
Atkinson, and Glasner 2008b). In all these contexts they offer the performative
potential of bringing the world they conjure into being.
Brosnan and Michael (2014) suggest a division of the sociology of expectations
literature into “structural” and “microsociological” approaches; the former focused
upon “regulatory frameworks, technologies, scientiﬁc ﬁelds” and the later upon
smaller scale activities, for instance, “the rhetorical structure of expectations”
(2014, 525). In this paper we demonstrate the inter-relatedness of the structural
and the micro through an inspection of the circulation and recycling of promissory
narratives through our focus upon ﬁeld, institutional, and individual expectations.
In our context the ﬁeld is biobanking, the institution is Xbank, and the individuals
are the staff who worked there.
Fields are, of course, sets of institutions, and institutions are sets of individuals.
At each level – ﬁeld, institution, and individual – expectations are in operation,
giving form to current practices and acting as performative frames of anticipated
future activities. These three levels of expectations are interrelated through their
mutual shaping and co-production (Jasanoff 2004; cf. Mayrhofer and Prainsack
2009). They are also the site of differences, both between and within levels. The
expectations of individuals can frame, and contest, those of the institution(s)
they work within, just as the institutional can frame and contest the ﬁeld and the
individual. Equally, multiple individuals within one institution or multiple insti-
tutions within one ﬁeld can frame, be framed, and contest the expectations of
each other. In this way expectations can be patterned institutionally, or by ﬁeld.
Different patterns of expectations can lead to conﬂict as some sets of expectations
challenge the performative character of others. The important social science insight
is that this patterning and layering can and should be mapped through empirical
investigation. Doing so provides a richness to our understanding of the dynamics
of expectations of a ﬁeld, an institution, and an individual.
In our case the data make clear the mutual shaping and exchange of expec-
tations between these levels during periods of change at Xbank. This mutual
shaping enables a recycling and reconﬁguration of expectations during and
beyond Xbank’s closure.
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Methods
The project is based upon qualitative ﬁeldwork conducted at Xbank. This site was
selected after Xbank’s Senior Manager approached the research team after
exposure to Stephens’ existing work with another biobank (cf. Stephens, Atkinson,
and Glasner 2008a, 2008b, 2011a, 2011b, 2013). Following this, we held initial
meetings and commenced documentary analysis. Five months later, we conducted
formal semi-structured interviews during three visits to Xbank over the course of a
year, with a follow-up telephone interview conducted with the Senior Manager as
Xbank was disbanding eight months later. All 5 members of staff active at Xbank
during the research process were interviewed, with 1 interviewed once, 1 inter-
viewed twice, 2 interviewed three times, and 1 interviewed four times over the
19-month period during which the closure occurred. We also carried out one tele-
phone interview with a member of Xbank’s oversight group close to the time of the
ﬁnal site visit. We only interviewed one member of this group because the commit-
tee members were reluctant to be interviewed. With hindsight this is understandable
as they were planning to make some Xbank staff redundant and may have felt it
inappropriate to share this with a social scientist studying the bank. In all, we com-
pleted 14 interviews with 6 individuals over a two-year research period, along with
observations at four workshop events run by Xbank and a network of disease-
speciﬁc biobanks. Given the small size of Xbank the documentary, interview,
and observational work form a robust and detailed data set. Stephens collected
the data before they were coded by Dimond and then analyzed and written up
by both. The coding used broad themes such as “promise”, “closure”, “patient
relations”, and “hospital activity”.
The Cardiff University School of Social Sciences Research Ethics Committee
approved the research and participants were provided with an information sheet
and required to sign an informed consent form. Our completion of the project
has required providing a signiﬁcant level of anonymity for the bank, its staff,
and the agencies it works with. Therefore, we do not reveal details of Xbank’s
location, the disease area in which it operates, or the dates of the events reported.
To allow us to retain date anonymity while indicating the passage of time between
interviews we date quotations by month and year 1 or 2 of our research period. We
provide the same level of anonymity for Xbank’s partner organizations. Xbank was
a member of a biobanking network that we refer to in this paper with the pseudo-
nym “Biobank Network”. Changes have been made to some interview quotations
to retain anonymity.
Establishing institutional promissory narratives: being aligned to, but
distinct from, the rest of the ﬁeld
Xbank was established with over E3m funding from two governmental and one
non-governmental organizations. This followed a period of regulatory upheaval
as government agencies sought to regain institutional and public trust for the
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mechanisms of human tissue use, storage, and movement, following a period of
raised ethical awareness about tissue retention. This resulted in the formation of
an arm’s length governmental body to regulate human tissue holdings. Xbank’s
Senior Manager articulates the situation as such:
The [new regulation] was passed in. [At the time our] funders got together and
decided it was time to kick off this [national tissue resource]. It has never been
said explicitly to me but certainly from a governmental perspective I have had the
strong impression that our launch was meant to demonstrate there was an antidote
to the perceived restrictions that had come about through the passing of the [new
regulation]. A lot of people were very anxious about the passing of the [new regu-
lation], it was something that was barely regulated before, [that] might become
very regulated. It would actually lead to more paralysis rather than facilitation of
human tissue based work. My governmental funders, I think, were keen to demon-
strate [that] actually there is life after the [new regulation]. (April year 1)
The original plan developed for Xbank by its funders was to commission an aca-
demic institution to act as a disease-speciﬁc biobanking center. This changed to
forming an independent charity separate from and neutral toward the research com-
munity and at arm’s length from the funders using the charitable trust model of bio-
banking similar to that recommended by Dixon-Woods et al. (2008). The Senior
Manager presented this institutional form as a response to recent regulatory and
public discordance on issues of tissue collecting:
I could see that, given the retained tissue scandals were all about a loss of trust, a
charitable trust like this would be a good thing to re-engage public support and
regain trust. (April year 1)
Demonstrating ethically legitimate practice was a key aspect of Xbank’s promis-
sory narrative. The organizational arrangement involved an oversight committee
that guided its activities and an additional independent ethics committee. Such
layering of decision-making within an institution is commonly exhibited in the
governance of bioscience where distance between those who make decisions and
those who carry them out is intended to prevent conﬂict of interest (Jasanoff
2005; Stephens, Atkinson, and Glasner 2013). The Xbank oversight committee
included experts in the ﬁeld, a patient representative, and representatives of their
funding bodies. The committee’s remit extended to the degree that, as we will
detail, it could order Xbank to cease biobanking activity.
In addition to these issues of trust and legitimacy, Xbank was also a response to a
disease-speciﬁc research evaluation that identiﬁed access to human tissue as a
recurrent problem for researchers in the ﬁeld. Subsequently the biobank was
devised to increase the ﬂows of deemed ethically sourced, data-linked, and
quality-assured human tissue to researchers, against a backdrop of unevenly distrib-
uted localized tissue collections. Again, according to the Senior Manager:
What we were asked to do by our funders . . . was quite innovative in some regards, it
. . . was to form a bank of samples for future undeﬁned purposes, where the potential
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downstream uses were maximised, as far as could be afforded. We weren’t collecting
samples for a speciﬁc project therefore we weren’t collecting to a speciﬁc protocol
that ﬁtted a speciﬁc use. We were collecting to a neutral protocol that would hopefully
ﬁt many potential uses in the future. And we were also trying to collect from multiple
sites in different parts of the country. (April year 1)
The bank collected blood and tissue samples from any diagnosed patient in the
afﬁliated hospitals who were willing to donate, providing it did not impact on
their clinical care. Xbank established its own accredited informed consent pro-
cedures agreed to by their ethics committee. It also established a network for
donors as an attempt to keep donors informed about biobanking practices and feed-
back donor viewpoints into Xbank’s operation. After donation the tissue collected
from patients would be distributed to researchers with an interest in a diversity of
related topics and institutional afﬁliations, although in practice Xbank ceased bio-
banking activities before it commenced distribution.
As well as collecting tissue Xbank was also mandated to perform a secondary
role of building a disease-speciﬁc biobanking network across the country to
promote networking and discussion of what was at that point perceived to be dis-
jointed national provision and practice in the ﬁeld. The Senior Manager explained:
[Our secondary role was to] promulgat[e] best practise, opinion leading, showing a
bit of behavioural leadership and trying to demonstrate that Xbank wasn’t about
Xbank. Xbank was about the bigger picture. We were there to provide a community
service and would be open in that regard. (April year 1)
To this end, Xbank worked with other colleagues to establish a disease-speciﬁc
network of biobanks – the Biobank Network – for which Xbank would later go
on to provide the ofﬁcial secretariat – as the central mechanism for promoting dis-
cussion and exchange. Both under its own name, and under the Biobank Network
rubric, Xbank staff organized a set of workshops and conferences on biobanking
governance, informed consent, and quality issues in tissue storage. The long-
term aspiration was to move toward a harmonization of practice in the ﬁeld that
could eventually result in a single “virtual biobank”, or “research portal” (Kaye
2011), based on seamless operations across the network so sample users making
tissue requests across the network would experience what seemed to them to be
a single institution.
We see here the inter-relatedness of ﬁeld and institutional expectations: Xbank
clearly sought to both operate in harmony with a broader set of ﬁeld-wide expec-
tations about secure supplies of ethically accredited tissue and, through networking
activity, to be active in giving form to these ﬁeld-wide interests. At the same time
Xbank also sought distinctiveness in its mission through neutral protocols, multiple
collection sites, and as disseminator of best practice. These institutional expec-
tations take form in dialogue with those of the ﬁeld.
In practice, however, this unity building role, and the position of being a chari-
table trust outside established academic modes of interaction, created challenges for
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Xbank. Staff recognized that being external to the research community meant
establishing new forms of trust relationships in an unfamiliar institutional
context. The Senior Manager related that:
The research community consists of those who can access human tissues for their
research, the “haves” and those who ﬁnd it difﬁcult, the “have nots”. And we were
there to neutralise that and level the playing ﬁeld, and the “haves” had a lot to lose
as a consequence, in their own mind. (April year 1)
She continued this point later in the interview:
To the “haves”, sometimes I was received a bit in the early days like the Antichrist
and to the “have nots” I was received a bit like the Messiah, so they both had unrea-
listic expectations of what the organisation, and me in particular as the leader of the
organisation, might do for them. (April year 1)
During the data collection period Xbank continued to work to build a biobanking
community against these pressures, and was able to demonstrate a level of success
in this area. While these challenges remained pertinent for the staff, it would not be
these relationships that eventually led to their closure. Instead it would be the chal-
lenges of their primary function – collecting disease-speciﬁc tissue – that proved
decisive in their cessation of biobanking activity.
The interview quotations presented so far reveal a network of expectations laced
throughout all aspects of Xbank’s early work. The establishment of Xbank was per-
ceived by the Senior Manager as an attempt to address fearful expectations about
the newly established regulatory body for human tissue. This formed part of a
broader promissory narrative about innovative forms of tissue supply from
patient-donors to research institutions that kept donors informed through their
own forum. Xbank’s structuring – as a charity with independent advisory commit-
tees – was intended to comply with broader expectations of ethically legitimate
practice. However, this resulted in perceived challenges about what other groups
in the same disease-speciﬁc biobanking ﬁeld expected of them, as either competitor
or savior. Our data also reveal the interrelated patterns of ﬁeld and institutional
expectations as Xbank sought to be both aligned to, and distinct from, the practices
of similar biobanks in the ﬁeld.
Working to deliver the promise: collecting tissue from patients
Xbank developed strategic allegiances with a number of hospitals to collect
tissue donations. All clinical trial networks within the national network of
hospitals in the appropriate disease areas were invited to submit a bid if they
wished to contribute. The ten bids received were reviewed by an independent
committee who chose the initial four hospital groups that formed the donation
networks. However, once chosen, Xbank subsequently found the hospitals did
not always perform quickly enough for their needs. The Senior Manager
reported that:
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The timelines of people within the hospitals just was on a different [scale] – it was on
a sort of geological timeframe relative to us. And so whilst we would say, “do you
think we could complete the negotiation and complete the contract between the hos-
pital and the charity here within the next three months?” [They would reply] “Yeah,
no problem”. Nine months later, no contract. And so that was (a), terribly frustrating
and (b), terribly disappointing. Because although people had goodwill there was no
action. And no action meant that we weren’t doing what we had been funded to do.
Our staff weren’t doing what they were being paid to do and their performance was
looking poor by comparison. (April year 1)
Subsequently one of the four hospital organizations was dropped from the working
relationship and Xbank pursued with the remaining three, two of which shared geo-
graphical proximity and formed one network. Each network involved an Xbank
employee positioned within each hospital to pursue the ethical sourcing and move-
ment of tissue into Xbank’s biobanking facility. During this period Xbank had been
developing their own systems for collecting quality-assured tissue via a Standard
Operating Procedure for collecting and logging it in a bespoke software system
that had been developed by Xbank’s in-house software development team. The
embedded employee in each hospital would process the samples provided by hos-
pital nurses who had been trained by Xbank in their consent procedures. Each hos-
pital group had suggested what they believed to be realistic targets for the quantities
of material they could provide in their bids to work with Xbank and these were sub-
sequently agreed with Xbank staff. However, our interview with the Senior
Manager revealed that achieving these targets in practice was more challenging
than expected:
One network, the two hospitals in one network, were exceedingly good. They got up
and running quickly, they enthusiastically adopted the StandardOperating Procedures,
they allowed us to implement the information management system and the sample
tracking mechanisms. And they did it without grumble and with great enthusiasm
and were a real beacon for what it was we were trying to do. However, they did ﬁnd
it difﬁcult to achieve anywhere near the number of patients that they had said they
could do in their bid. So that was the other lesson, unrealistic expectations from
people in the healthcare service. They would say, yeah, we [have] X number of thou-
sands of patients a year, if we only found time to approach 10% of those and 99% of
those consented, it would still end up in X thousands of patients donating. Nowhere
near it. In fact, the best performing place probably were about 40% of what they pre-
dicted. Which then of course didn’t reﬂect well on the charity when it was then report-
ing to its funders. And it was a sort of knock on effect. And so false expectations were a
really difﬁcult thing to deal with in all levels. (April year 1)
The numbers of samples collected were also affected by the micro-organization of
the movement of materials within the hospital and between hospital and Xbank
staff. With only one employee on site, Xbank required a steady supply of tissue
for processing, but this was not always possible. Another biobank manager
reported:
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For quality reasons we’d set a tight time schedule, so half an hour from [the nurses]
taking the blood from the patient to [the embedded Xbank employee] processing it,
and once you start processing you’re tied up for an hour in the complexity of the pro-
cessing. [The Xbank employee is] getting samples from a number of different nurses,
so there had to be a degree of coordination where nurses were phoning her up and
saying, “I’ve got a patient here can you take a sample now” and she’d be saying
“I’m up to my eyes in the lab, can you do it in half an hour,” so that was a bit of
an issue. (Manager 1, April year 1)
At times the embedded Xbank staff member was too busy to collect all the samples
made available. However, there were also times when there was too little for the
Xbank staff member to do:
And then we hit half term [in the school system] and the nurses all went off . . . on
holiday and the other nurses who are left are having to ﬁll in with the clinical side
of dealing with the patients so they stopped seeking consent and taking blood . . .
[which means] I’ve got a [staff member] sitting there for two weeks twiddling her
thumbs, costing me a lot of money . . . and it wasn’t just half term, it would be,
“oh, somebody’s left we’re really short staffed, oh look a second person’s left”.
[So we would ask] “can’t we just recruit somebody?”; “Well no, this is the hospital
system, it takes a long time to get permission to recruit”. It could take months and
months. (Manager 1, April year 1)
Broader institutionally patterned expectations around productivity and imagined
timelines – and the differences between these in the different institutional contexts
of Xbank and the hospital system – shape the day-to-day micromanagement of bio-
banking and hospital practice. In this context, sets of personal and institutional
expectations are co-produced with the evident frustrations when they are not
met. In this case expectations were not being met because time pressures on hospi-
tal staff, and in some instances the Xbank staff employee, inhibited their collective
ability to ensure the timely and steady passage of tissue from patients into the
banking system. Sometimes the patients were not asked, sometimes the hospital
did not take blood, and sometimes material that was available could not be deliv-
ered and dealt with at the processing facility within the required timeframe.
We have already noted the challenge recognized at Xbank of being located
outside of networks of academic institutions. It is clear they also perceived chal-
lenges in being outside the formal healthcare system, particularly in terms of
assumptions made about employment and ﬁnances. Manager 1 noted that:
It was clear they had some expectation of us that we weren’t in a position to fulﬁl,
they saw us as outside the formal healthcare system, using healthcare system facilities
and the normal people who do that are pharmaceutical companies for your clinical
trials who are a lot richer than we are. We were funded at a level where we shouldn’t
be a cost burden on the hospitals but they weren’t going to make any money out of us,
so we were able to offer them funding for one full time [ . . . ] post, up to them to
decide how to deploy it. (April year 1)
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This theme is continued in the Senior Manager’s account:
And sadly, although [a senior governmental ofﬁcial] thought we were important, they
supported us, when you got to the operational level in hospitals we were really small
fry. The income that was generated from working with us, which is on an ethically
titrated reimbursement process so nobody was proﬁting out of this relationship, . . .
was so insigniﬁcant to the operating budget of the hospital that it didn’t excite any
interest whatsoever. Staff who were directly involved were often quite passionate,
but they couldn’t get the interactions with other staff that were necessary in the life
of the patient that they needed to access to get interested. Because it wasn’t their
job, it wasn’t what they were about, it was a distraction, it was an inconvenience
sometimes. And the one thing we didn’t want to try and do at any point was engineer
any care pathway activity for our beneﬁt, because that should always be for the
patient’s care beneﬁt. (April year 1)
This account articulates the divided interests and expectations of multiple individ-
uals within the hospital system, and how these frame and contest the performative
registers of Xbank and its close associates. Extending this, micro-level time man-
agement and funding concerns were seen as further exacerbated by structural
policies:
The ﬁnal, I suppose – I’ll call it nail in our cofﬁn in terms of this activity, was that the
government launched [a new body to co-ordinate funds for research within the
national hospital system]. It was a big endeavour, it was a ﬂagship activity, it was
well planned, well thought out, well delivered, well funded. It was all about high
quality research and it was all about high quality hypothesis driven research . . .
when it became clear that the government weren’t going to create a special category
that allowed data banking or tissue banking to gain recognition, and therefore respect-
ability within hospital institutions, it was clear that this wasn’t going to work. (Senior
Manager, April year 1)
At this point in time, Xbank’s primary promise was to establish a stock of tissue for
subsequent distribution and to do so at a certain rate. The interview extracts show
that Xbank’s staff describe difﬁculties in leveraging sufﬁcient activity within the
signiﬁcantly bigger hospitals with their own ways of structuring their time and
incentives. Each organization – Xbank and the hospitals – had different institu-
tionally patterned expectations of how the other would perform, and, as the
Senior Manager noted, this had implications for how Xbank was judged in line
with the expectations placed upon its own activities. Activity at the hospitals, as
part of a wider hospital system, was framed by broader interests stipulated by gov-
ernment and materialized in their new funding coordination body. This new pattern
of expectations, and the types of performativities it afforded, stood in conﬂict with
those of Xbank. This section has also conﬁrmed the familiar observation that
expectations are often not met and promises often not delivered. What is distinct
in this example is that this cycle of promise and disappointment happened so
swiftly.
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Expectations missed and expectations reconﬁgured: notiﬁcation of cessation
of biobanking activity
Four years after being established, Xbank received ofﬁcial directions from their
oversight committee to cease biobanking activity. The committee was disappointed
that the donation networks were not collecting tissue at the rate dictated by their
targets. The committee was also aware that other banks in the same sector were
experiencing a difﬁcult relationship with Xbank because Xbank could be perceived
in multiple roles as a disseminator of best practice, a collaborator, and a competitor.
The Xbank staff were informed of the cessation ﬁve months before it was made
public, but could predict the likely outcome earlier again:
[We were informed] after Christmas, but to be honest we had a meeting in about Sep-
tember and we had a [sample collection] target which we had to reach. And it was
obvious from the rate that we were getting samples in that we would never reach
it. (Technician, April year 1)
However, while falling below the sample collection target caused signiﬁcant dis-
ruption for Xbank, it did not bring an end to the organization altogether. The fol-
lowing interview extract draws together both the problems in meeting the initial
expectations placed upon the organization, and the subsequent reconﬁguration of
these expectations into something new, as Manager 1 reﬂected:
We were not as successful at recruiting patients and getting samples in as we hoped
we would be. [The Senior Manager] and I actually set ourselves targets, we were told
to by the oversight committee, in terms of numbers of patients and types of speci-
mens. We went round and talked to all the networks and said “look you know
we’ve been given these targets and if we’re to achieve them you need to enrol this
number of patients and it’s way below what you said you could, get on with it”,
that still wasn’t successful even with that sort of level of pressure on the networks.
Everything that’s in our complete control, we’ve achieved. It’s things where we’ve
had to rely on other people that has been much more difﬁcult to get to where we
would want to be. So after Christmas it became clear that the committee had
decided that we wouldn’t be re-funded and therefore we couldn’t carry on the way
we were carrying on. If we carried on collecting specimens we would run out of
money relatively quickly and so we would need to stop collecting specimens and
change the focus of the organisation. It was a surprise that they wanted to change
the focus of the organisation. Because I really thought they would close us down
completely. But we’re very pleased that what they saw is that our secondary role pre-
viously was more successful than our primary role. So we just switched the emphasis.
They’re not giving us any more money, but we’ll last for a while on the funds we’ve
got and there’s something to prove isn’t there, you know to see how successful we can
be. (April year 1)
In this quotation we can see frustration, disappointment, pride in previous work
achievements, and recognition of problems, followed by surprise, happiness, a
reconﬁguration of expectations, and a new drive to achieve. The oversight
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committee had decided to halt biobanking activity as soon as possible to allow the
remaining budget to be spent on a new reconﬁgured Xbank, focusing upon what
had been their secondary role of facilitating exchange between the broader bio-
banking community. Maintaining biobanking activity, needing a larger staff and
expensive facilities have a higher monthly cost than their advisory role so the re-
focusing would extend its lifetime by around two years. A member of the oversight
committee who was involved in this decision recounts:
There was always a cold sense of reality from the beginning. There was a sense of
“are we trying to do something that’s impossible here?” But at the same time we
believed that there still needed to be somewhere where the [research] community
would like to go. (April year 2)
And later in the interview:
I think [the mood on the committee was] just very pragmatic, and realistic and very
honest. We had for perhaps 18 months now, been thinking “what if we don’t do this?”
And if we don’t do it, what are we doing instead or how are we taking this forward?’
. . . I think [the Senior Manager’s] role within the community of getting on and doing
some things, which she is excellent at, helped the committee come to a conclusion
that actually, you know, the Network could be a helpful way forward here. So I
don’t think there was a sense “we’ve done something terrible here”. It was very
much, a pragmatic “well, you know, this is really not going to function at this
present time”. (April year 2)
As part of re-focusing Xbank on a new role and a new set of promises, the old
promises, and the structures that supported them, also had to be dismantled:
There’s also that element whereby people do feel failure even if failure wasn’t of their
doing. We’ve had to lose staff here which was a painful experience. Well, it was a
painful experience for others, I just had to do it because that was my job and I’ve
done it before, it’s not nice but it comes with the turf. But for the others the mood
in the ofﬁce was very poor for a long time. (Senior Manager, April year 1)
Redundancy produced a sharp severing of once aligned personal and institutional
expectations. Those who remained redrew personal expectations in accordance
with a novel institutional narrative and novel institutional spaces:
It’s been quite unpleasant because obviously we’ve had to make redundancies and
you know it’s not been very nice and because we’re still in the ofﬁce here, we
own this massive ofﬁce [with] only four of us. It is getting better but I think once
we move ofﬁces it will sort of like wipe the slate clean and start again. (Personal
Assistant to the Senior Manager, April year 1)
This is an emotional as well as institutional change that weaves personal narratives
of affect and career together with the institutional promissory narratives of Xbank:
I have a different job title, I have a different job, it’s been horrible, I mean personally
. . . [the Senior Manager] describes it as survivor guilt, because I’m intrinsic to the
things that didn’t work, and hey I’m still here and the IT team and the quality
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manager have had to go. My job hasn’t changed completely because a lot of it is still
dealing with samples and cells and [the Technician is] still here, although he knows
that his time’s limited. (Manager 1, April year 1)
Here we see how personal expectations, just as institutional expectations, hold a
performative character, as role, job title, and personal identity are co-produced.
As staff exited Xbank, and the initial promise faded, the question of what should
be done with the collected material occupied those who remained. In practice much
of it was returned to the hospitals from which it was collected, with a limited quan-
tity distributed for research purposes and a proportion passed to another emergent
biobank. The remainder was destroyed as Xbank refocused its activities and refor-
mulated its promissory narrative. It is in this section, in a moment of rupture in
Xbank’s practice, that both the relatedness and the breakdown of institutional
and individual expectations become most visible.
Establishing new institutional promissory narratives, and recycling old
ones: Xbank with a new reconﬁgured role
In its new role, a streamlined Xbank of four staff members continued to organize
workshops and events on consent issues and Quality Assurance. New promises
brought with them new social relations as Xbank ceased to be a competitor bank
to others in the ﬁeld and instead focused more clearly on a leadership role. The
Senior Manager reported that:
It has been announced just today that the secretariat function [of the Biobank
Network] will be subcontracted to ourselves, given our change in remit. And given
the fact that we conceived the idea of the Network in the ﬁrst place and made it
happen right at the beginning, they’re now turning the leadership of it over to us.
The presumption is that we’ve both got the experience in the ﬁeld, the energy and
enthusiasm, the funding and now that we’ve changed our remit the time to provide
this leadership coordination and energy to drive the ﬁeld forward. Coupled with
the fact that we’re now backing out of active biobanking perhaps there’s less of a
competitive tension as a consequence as well. So although the Network and the pro-
mulgation of standards and harmonisation and all that sort of stuff was a secondary
endeavour in our previous business plan, it’s now what it’s all about for us. (Senior
Manager, April year 1)
This enthusiasm for the Biobank Network is echoed by a member of the oversight
committee:
I think people are now buying into [the Biobank Network] because it does something.
It’s begun to bring the members together. It’s giving them an initial sense of commu-
nity. It’s the place to be for the dialogue and to hear what the latest thinking in bio-
banking is about. (Oversight committee member, April year 2)
In this new role Xbank worked on making other elements of their initial promise
continue in a new form:
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Well we’ve kind of killed the Xbank network for donors but it’s going to be reborn
like a phoenix as the network for donors for the Biobank Network, and [Manager 2]
has a speciﬁc objective to relaunch it, but for people who have donated to pretty much
any biobank. (Senior Manager, November year 1)
And in turn these reconﬁgured promissory narratives became something
that Xbank staff were keen to instantiate in practices sufﬁciently robust to
survive the type of organizational change experienced at Xbank, as detailed by
Manager 2 who worked to relaunch the network for donors for the Biobank
Network:
So I think it’s just kind of trying to promote an awareness of things like the Biobank
Network so that potentially when Xbank is not around anymore then that’s kind of got
a momentum of its own and other people can run it. (Manager 2, March year 2)
We can understand this movement into Network leadership as a reconﬁguration,
and in some regards a recycling, of the initial Xbank promissory narrative.
While Xbank would no longer be the active tissue resource disseminating best prac-
tice, in this new form it still promised to shape a broader community in which these
values remained present. In this way we cannot say the initial promise of Xbank
was entirely lost when biobanking ceased. Indeed, as the following interview
extract illustrates, some promises proved resilient:
We had consent from donors to bank the material with Xbank. [Since the reconﬁgura-
tion of role] we’re actually passing it onto another biobank which we hadn’t really
envisaged in the consent documents. We took broad consent so it does cover it. It
just isn’t explicit in the things that we gave to donors in the ﬁrst instance. But
what we are absolutely doing is passing on to the other biobank all the other promises
that we made to the donors about what types of research their samples would be used
for. So written into the materials transfer agreement is a clause that says you promise
not to go looking for who these donors are. (Manager 1, November year 1)
Xbank’s reconﬁgured role did not result in the absolute dissolution of all of their
initial promise. Some – like the goals of sharing best practice and the network
for donors – were repackaged in their new work. Others – like the consent and
treatment of the tissue – traveled with the tissue into new biobanking infrastruc-
tures. In doing so, they become part of the institutional promissory narratives of
other institutions elsewhere within the ﬁeld, highlighting the recycling and
trading of expectations across ﬁeld and institution.
Recycling individual expectations: Xbank’s ﬁnal closure
During this period of reconﬁgured activity, staff at Xbank remained apprehensive
about the long-term future of the organization, and how the promises and expec-
tations around the organization’s activities mapped onto their expectations and
hopes around their own personal career trajectories. The uncertainty that this
invokes is described by the Senior Manager:
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Wewill be barely into our last full year of doing it and we may get an indication at that
point that life will be over after we do that. And of course at this point it’s already
destabilising the staff, and it’s likely to signiﬁcantly destabilise the staff at that
point. So there’s always a risk that we won’t get through the next budget year.
Because if the omens are bad then people will naturally look towards their own per-
sonal and ﬁnancial futures and ﬁnd other jobs. So we may not fulﬁl these plans. And
that applies to us all, it applies to me as well as it does to any of the staff, because
times are tight and we are quite niche in our work. And employment opportunities
are few and far between. We’re doing well and we’re doing our best. The future
however and the destabilising inﬂuence of the uncertainty that exists at this point
and the certainty that may exist in about June time may be very disruptive. (March
year 2)
Then, in October, the oversight committee made another announcement stating
that, while a sub-section of the advisory activities of Xbank should continue,
they should be conducted by other organizations. This decision signaled the
closure of Xbank, the disbandment of the remaining staff, and the end of the
Xbank name.
Two of the remaining four staff – Manager 1 and Manager 2 – became employ-
ees of a national research organization continuing the work of the Biobank
Network, while the remaining two – the Senior Manager and his Personal Assist-
ant – sought employment elsewhere as Xbank ceased to exist:
[Manager 1 and Manager 2] are currently in the employment transfer process prob-
ably meaning completion at the beginning of January. They will actually physically
move out of this ofﬁce at the beginning of December . . . On that basis I’ll be the last
person here and I’ll serve notice on the ofﬁce and be out of the ofﬁce by Christmas
time so this facility from where I’m speaking to you now will not be ours any more.
Then the remaining piece of the jigsaw is me because the organisation has to be
closed before I leave so the long stop date on that will be 31st March, but I want
to have secured and started new employment prior to then and so therefore the
ﬁnal closedown . . . in my mind [will] be sometime between the beginning of
January and the end of March. After I lose the ofﬁce I’ll continue to work from
home with regular visits to the [national research organisation] ofﬁces. There’s a
hot desk arrangement . . . I expect something’ll work out [for me]. I’ve got some
irons in the ﬁre. (Senior Manager, November year 2)
Xbank no longer exists but aspects of its initial set of promises are still being
pursued. Xbank Manager 1 became employed by a national organization focused
on the same disease type as Xbank, working toward biobank harmonization, certi-
ﬁcation, and accreditation, including involvement in a national project aiming to
increase the efﬁciency of biobanking through shared practice. Manager 2 moved
to the same national organization and continued to perform a similar role producing
the Biobank Network newsletter and represents their secretariat. Both are examples
of the recycling of promises through new institutional spaces and funding sources,
just as both are examples of individuals who have reconﬁgured their personal
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expectations and career narratives through these processes of institutional reformu-
lation. The Senior Manager’s PA successfully secured employment elsewhere
before redundancy, while the Senior Manager was subsequently employed in a
senior management position working on biobanking internationally.
Conclusion
In this paper we aimed to make three distinct contributions: (i) to detail the story of
Xbank through establishment, operation, and closure, making clear the rapid turn-
over in promise and disappointment; (ii) to develop an understanding of expec-
tations layered across the levels of individual, institution, and ﬁeld; and (iii), to
use this typology to make explicit the mechanisms underpinning the recycling
and reconﬁguring of expectations at Xbank. We have achieved this through relating
a detailed exposition of our interview data to the sociology of expectations litera-
ture, and our own focus on individual, institutional, and ﬁeld expectations within it.
Xbank, like many other biobanking initiatives, was launched with a set of ambi-
tious and admirable promises. These goals arose from a political context valuing
research into disease against a backdrop of heightened concern and new regulatory
procedures about storing human tissue. For Xbank this meant collecting ethically
sourced tissue from patient-donors to a neutral protocol that could then be efﬁ-
ciently distributed for research purposes. This involved developing ethically accre-
dited practices, bespoke computer software providing a searchable catalogue of the
tissue holdings, and institutional networks providing robust supplies of tissue from
hospitals into their biobanking facility. In practice it was the inability to achieve
sufﬁcient supply of tissue in the given time frame that led the oversight committee,
facing a progressively tight ﬁnancial environment, to decide the remaining money
was best spent supporting Xbank’s secondary role in supporting best practice and
that biobanking activities should cease. Xbank staff point to the unrealistic expec-
tations provided by the hospitals about the likely levels of tissue that would be sup-
plied and inertias and disincentives within the hospital system organization itself as
key factors in generating the problems encountered.
We have detailed a cycle of promise, disappointment, the reconﬁguration of
these promises, another period of disappointment, and ﬁnally noted the re-emer-
gence of these promises again in a new institutional context. This institutional
story reveals rapid turnover in multiple cycles of expectations in which the perfor-
mative aspect of employing future-orientated accounts to shape current practice
broke down quickly, only to be reconﬁgured in a new form. It is not the case
that the promise of Xbank simply ceased when biobanking ceased. Instead
aspects of the promissory narrative took new forms sometimes in new institutional
contexts. Sometimes these promises moved with the tissue, as in the research
potential of sample use; sometimes they moved with legal documents, as in the
commitments to ethical protections; and other times they move with the staff them-
selves, as in the commitment to standardizing best practice and establishing a
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network for donors. We focused upon these staff members to highlight how they
exist both as carriers of promise and as individuals who make sense of their identity
through professional and affective personal narratives that were framed by the
ongoing tension between Xbank’s broader institutional promissory narrative and
the precariousness of its uncertain funding base. This provides evidence of the
mutual shaping of ﬁeld, institutional, and individual expectations as they frame
and contest each other.
The novelty of the Xbank example is the swiftness with which the performativity
of institutional expectations was broken as biobanking activity ceased. Our case
study makes the distinctive observation that expectations can both be reconﬁgured
quickly, and remain remarkably robust even through reconﬁguration. We have
shown that through the dynamics of ﬁeld, institution, and individual relations,
expectations can be recycled and traded through legal, personal, and material cir-
cuits within a ﬁeld. Indeed it is the moment of closure of Xbank that demonstrates
how resilient expectations can be as they shift between layers and between insti-
tutional contexts.
While our focus is biobanking, we propose that analysis using ﬁeld, institutional,
and individual expectations should be fruitfully pursued in other settings both
within biomedicine and beyond. The framework is intended to be ﬂexible, to
be deployed, and be responsive to the speciﬁcities of each particular research
site. We offer it as a mechanism to engage across the division between structural
and microsociological approaches to the sociology of expectations (Brosnan and
Michael 2014) by linking an analysis of multiple levels from the broadest
to the individual. It is the analysis of the layering and relatedness of these levels
that allowed us to articulate the recycling of promise across the ﬁeld. The frame-
work invites us to inspect the institutional and ﬁeld level patterning of expectations,
recognizing the contestation and co-production both across and within them
(Jasanoff 2004; Mayrhofer and Prainsack 2009). It supports us in recognizing
performative registers at multiple sites and multiple scales, while remaining
within the established body of work on the sociology of expectations. This has
brought a richness to our own analysis, which we hope will prove valuable to
others.
Finally, following Zawati, Borry, and Howard (2011), Cadigan et al. (2013,
2014) and Caulﬁeld et al. (2014), we urge further work inspecting the real-world
experience of biobank failure, underutilization, merger, and termination. Increased
consideration of contingency planning, closure policies, and the availability of
advice for best practice during mergers and closures is required to better support
a sustainable biobanking ﬁeld and sustainable biobanking institutions. As soon
as any biobank opens, the possibility of closure exists, and the practical impli-
cations of this require analysis and foresight. The case of Xbank invites us to
remember that while tissue banks promise to lend stability to the supply of ethically
sourced human tissue, in reality, as institutions, they can struggle for stability
themselves.
New Genetics and Society 433
D
ow
nl
oa
de
d 
by
 [B
ru
ne
l U
niv
ers
ity
 L
on
do
n]
 at
 06
:41
 27
 N
ov
em
be
r 2
01
5 
Acknowledgements
We would like to thank our participants for their willingness to participate in this research during this
period. We also thank the Cesagen journal club and an anonymous reviewer for their comments on
this paper.
Disclosure statement
No potential conﬂict of interest was reported by the authors.
Funding
The support of the UK’s Economic and Social Research Council (ESRC) is gratefully acknowledged.
This work is part of the research program of the ESRC Genomic Network at Cesagen (ESRC Centre
for Economic and Social Aspects of Genomics RES-145-28-0003).
References
Bakker, S. 2010. “The Car Industry and the Blow-out of the Hydrogen Hype.” Energy Policy 38 (11):
6540–6544.
BioInform. 2006. “Resurrecting Ardais Biobanking Technology; Gulfstream Bets on Pure-Play Soft-
ware Model.” Genomeweb.com. Accessed June 12, 2013. http://www.genomeweb.com/print/
650373.
Brosnan, C., and M. Michael. 2014. “Enacting the ‘Neuro’ in Practice: Translational Research,
Adhesion and the Promise of Porosity.” Social Studies of Science 44 (5): 680–700.
Brown, N., and A. Kraft. 2006. “Blood Ties: Banking the Stem Cell Promise.” Technology Analysis
and Strategic Management 18 (3): 313–327.
Brown, N., and M. Michael. 2003. “A Sociology of Expectations: Retrospecting Prospects and Pro-
specting Retrospects.” Technology Analysis and Strategic Management 15 (1): 3–18.
Brown, N., B. Rappert, and A. Webster. 2000. Contested Futures: A Sociology of Prospective Science
and Technology. Aldershot: Ashgate.
Cadigan, R. J., E. Juengst, A. Davis, and G. Henderson. 2014. “Underutilization of Specimens in Bio-
banks: An Ethical as Well as a Practical Concern?” Genetics in Medicine 16 (10): 738–740.
Cadigan, R. J., D. Lassiter, K. Haldeman, I. Conlon, E. Reavely, and H. Henderson. 2013. “Neglected
Ethical Issues in Biobank Management: Results from a U.S. Study.” Life Sciences, Society and
Policy 9 (1). http://www.lsspjournal.com/content/9/1/1
Caulﬁeld, T., S. Burningham, Y. Joly, Z. Master, M. Shabani, P. Borry, A. Becker, et al. 2014. “A
Review of the Key Issues Associated with the Commercialization of Biobanks.” Journal of
Law and the Biosciences 1 (1): 94–110.
Chang, A. L. 2011. “Biobank Shutdown.” The Straits Times. Accessed June 12, 2013. http://www.
healthxchange.com.sg/News/Pages/Biobank-Shutdown.aspx.
Chiles, R. 2013. “If They Come, We Will Build It: In Vitro Meat and the Discursive Struggle Over
Future Agrofood Expectations.” Agriculture and Human Values 30 (4): 511–523.
Coleman, R. A. 2010. “A Human Approach to Drug Development: Opportunities and Limitations.”
Alternatives to Laboratory Animals 38 (Supplement 1): 21–25.
Dixon-Woods, M., D. Cavers, C. Jackson, B. Young, J. Forester, D. Heney, and K. Pritchard-Jones.
2008. “Tissue Samples as ‘Gifts’ for Research: A Qualitative Study of Families and Pro-
fessionals.” Medical Law International 9 (2): 131–150.
Hedgecoe, A. 2004. The Politics of Personalised Medicine: Pharmacogenetics in the Clinic. Cam-
bridge: Cambridge University Press.
434 N. Stephens and R. Dimond
D
ow
nl
oa
de
d 
by
 [B
ru
ne
l U
niv
ers
ity
 L
on
do
n]
 at
 06
:41
 27
 N
ov
em
be
r 2
01
5 
Hedgecoe, A., and Martin, P. 2003. “The Drugs don’t Work: Expectations and the Shaping of Phar-
macogenetics.” Social Studies of Science 33 (3): 327–364.
Jasanoff, S. 2004. “The Idiom of Co-production.” In States of Knowledge: The Co-production of
Science and Social Order, edited by S. Jasanoff, 1–13. London: Routledge.
Jasanoff, S. 2005. Designs on Nature. Woodstock: Princeton University Press.
Johnson, C. Y. 2013. “UMass Stem Cell Lab to Close.” Boston.com. Accessed June 12, 2013. http://
www.boston.com/business/healthcare/articles/2012/06/28/umass_stem_cell_bank_to_close_after_
state_funding_runs_out/..
Kaye, J. 2011. “From Single Biobanks to International Networks: Developing e-Governance.”Human
Genetics 130 (3): 377–382.
Kitzinger, J., and C. Williams. 2005. “Forecasting Science Futures: Legitimising Hope and Calming
Fears in the Embryo Stem Cell Debate.” Social Science and Medicine 61 (3): 731–740.
Koay, P., and R. Sharp. 2014. “Managing Expectational Language: Translational Genetic Pro-
fessionals Consider the Clinical Potential of Next-generation Sequencing Technologies.” New
Genetics and Society 33 (2): 126–148.
Lipworth, W., R. Forsyth, and I. Kerridge. 2011. “Tissue Donation to Biobanks: A Review of Socio-
logical Studies.” Sociology of Health and Illness 33 (5): 792–811.
Lo¨scha, A. 2006. “Anticipating the Futures of Nanotechnology: Visionary Images as Means of Com-
munication Technology.” Technology Analysis & Strategic Management 18 (3–4): 393–409.
Mayrhofer, M., and B. Prainsack. 2009. “Being a Member of the Club: The Transnational (Self-)Gov-
ernance of Networks of Biobanks.” International Journal of Risk Assessment and Management 9
(12): 64–81.
McCook, A. 2011. “Death of a Pathology Centre: Shelved.” Nature 476: 270–272. doi: 10.1038/
476270a.
Murtagh, M., I. Demir, J. Harris, and P. Burton. 2011. “Realizing the Promise of Population Biobanks:
A New Model for Translation.” Human Genetics 130: 333–345.
Pickersgill, M. 2011. “‘Promising’ Therapies: Neuroscience, Clinical Practice, and the Treatment of
Psychopathy.” Sociology of Health and Illness 33 (3): 448–464.
Pollock, N., and R. Williams. 2010. “The Business of Expectations: How Promissory Organizations
Shape Technology and Innovation.” Social Studies of Science 40 (4): 525–548.
Seiffert, D. 2013. “SeraCare Sells Biostorage Business, Restructures Business Around Diagnostics.”
Boston Business Journal. Accessed June 12, 2013. http://www.bizjournals.com/boston/blog/
bioﬂash/2013/01/seracare-sells-biostorage-business.html?page=all.
Stephens, N., P. Atkinson, and P. Glasner. 2008a. “The UK Stem Cell Bank: Securing the Past, Vali-
dating the Present, Protecting the Future.” Science as Culture 17 (1): 43–56.
Stephens, N., P. Atkinson, and P. Glasner. 2008b. “The UK Stem Cell Bank as Performative Archi-
tecture.” New Genetics and Society 27 (2): 87–99.
Stephens, N., P. Atkinson, and P. Glasner. 2011a. “Documenting the Doable and Doing the Documen-
ted: Bridging Strategies at the UK Stem Cell Bank.” Social Studies of Science 41 (6): 791–813.
Stephens, N., P. Atkinson, and P. Glasner. 2011b. “Internationaliser des standards, metter en banquet
avec conﬁance: La mise en banquet de cellules souches s trois syste`mes nationaux.” Revue
D’anthropologie des Connaissances 5 (2): 260–286.
Stephens, N., P. Atkinson, and P. Glasner. 2013. “Institutional Imaginaries of Publics in Stem Cell
Banking: The Cases of the UK and Spain.” Science as Culture 22 (4): 497–515.
Thrift, N. 2006. “Re-inventing Invention: New Tendencies in Capitalist Commodiﬁcation.” Economy
and Society 35 (2): 279–306.
Tupasela, A., and N. Stephens. 2013. “The Boom and Bust Cycle of Biobanking – Thinking Through
the Life Cycle of Biobanks.” Croatian Medical Journal 54: 501–503.
Tutton, R. 2007. “Banking Expectations: The Promises and Problems of Biobanks.” Personalised
Medicine 4 (4): 463–469.
New Genetics and Society 435
D
ow
nl
oa
de
d 
by
 [B
ru
ne
l U
niv
ers
ity
 L
on
do
n]
 at
 06
:41
 27
 N
ov
em
be
r 2
01
5 
Van Lente, H. 1993. Promising Technology: The Dynamics of Expectations in Technological Devel-
opments. Amsterdam: Proefschrift.
Vaught, J., J. Rogers, T. Carolin, C. Compton. 2011. “Biobankonomics: Developing a Sustainable
Business Model Approach for the Formation of a Human Tissue Biobank.” Journal of the
National Cancer Institute Monographs 2011 (42): 24–31. doi:10.1093/jncimonographs/lgr009.
Zawati, M., P. Borry, and H. Carmen Howard. 2011. “Closure of Population Biobanks and Direct-To-
Consumer Genetic Testing Companies.” Human Genetics 130 (3): 425–432.
436 N. Stephens and R. Dimond
D
ow
nl
oa
de
d 
by
 [B
ru
ne
l U
niv
ers
ity
 L
on
do
n]
 at
 06
:41
 27
 N
ov
em
be
r 2
01
5 
